680 related articles for article (PubMed ID: 18047782)
1. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
4. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
Reis AO; Cordeiro JC; Machado AM; Sader HS
Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
9. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.
Tsai HY; Liao CH; Chen YH; Lu PL; Huang CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Jun; 56(6):3402-5. PubMed ID: 22491684
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
11. Molecular Epidemiology of Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Clinical Specimens in the Northwest of Iran.
Jahansepas A; Ahangarzadeh Rezaee M; Hasani A; Sharifi Y; Rahnamaye Farzami M; Dolatyar A; Aghazadeh M
Microb Drug Resist; 2018 Oct; 24(8):1165-1173. PubMed ID: 29708837
[TBL] [Abstract][Full Text] [Related]
12. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
Tamma PD; Hsu AJ
Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Rybak MJ; Hershberger E; Moldovan T; Grucz RG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
Patel R; Gallagher JC
Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
[TBL] [Abstract][Full Text] [Related]
18. Typing of Enterococcus spp. strains in 4 hospitals in the Małopolska region in Poland.
Talaga K; Odrowąż-Konduracka D; Paradowska B; Jagiencarz-Starzec B; Wolak Z; Bulanda M; Szczypta A
Adv Clin Exp Med; 2018 Jan; 27(1):111-117. PubMed ID: 29521051
[TBL] [Abstract][Full Text] [Related]
19. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
20. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]